Sara Tarruella-Lopez

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 06, 2026

Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 05, 2026

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.

Journal: Breast cancer research : BCR

Published: September 10, 2025

Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM).

Journal: Therapeutic advances in medical oncology

Published: July 18, 2025

Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.

Journal: Breast cancer research and treatment

Published: July 14, 2025

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.

Journal: The oncologist

Published: May 07, 2025

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.

Journal: Journal of the National Cancer Institute

Published: March 11, 2025

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.

Journal: The Lancet. Oncology

Published: February 13, 2025

Effects of presurgical HIIT in hormone receptor-positive, HER 2-negative breast cancer cases: Two case reports from the GEICAM EFiK study.

Journal: Physiological reports

Published: February 05, 2025

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies.

Journal: The oncologist

Published: August 28, 2024

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 20, 2024

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry.

Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.

Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM).

Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM).

Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.

Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.

Effects of presurgical HIIT in hormone receptor-positive, HER 2-negative breast cancer cases: Two case reports from the GEICAM EFiK study.

Effects of presurgical HIIT in hormone receptor-positive, HER 2-negative breast cancer cases: Two case reports from the GEICAM EFiK study.

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies.

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies.

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.